Opinion
Calcineurin Inhibitors in COVID-19: Lessons Learnt
from Transplantation Medicine
René Hage1,2*, Carolin Steinack1,2 and Macé M Schuurmans1,2
Author Affiliations
1University Hospital Zurich, Division of Pulmonology, Switzerland
2University of Zurich, Faculty of Medicine, Switzerland
Received: July 25, 2020 | Published: August 10, 2020
Corresponding author: René Hage, University Hospital Zurich, Division of Pulmonology, Faculty of Medicine, Switzerland
DOI: 10.26717/BJSTR.2020.29.004802
Disease caused by the Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2) called COVID-19 is spreading rapidly
around the world. A definitive therapy is not available, and vaccines
to prevent COVID-19 are under investigation. We suggest that for
first-line treatment of COVID-19 we can learn from the experiences
of transplant medicine.
After transplantation of solid organs, such as after lung-,
renal, heart- or livertransplantation, patients always need lifelong
immunosuppressive therapy to prevent organ rejection, in most
patients this is dual or triple immunosuppression. COVID-19 poses
a dilemma in Solid Organ Transplant (SOT) recipients [1]. There are
no evidence-based guidelines how to deal with immunosuppression
in SOT recipients with COVID-19. Among the immunosuppressive
drugs, Calcineurin Inhibitors (CNIs) are extremely important in
preventing rejection. CNI is a calcium-calmodulin-activated serine/
threonine-specific phosphatase. Tacrolimus and cyclosporin are
well-known CNIs in transplant medicine. Inhibiting calcineurin
results in blockade of the translocation of the nuclear factor of
activated T cells from the cytosol into the nucleus, in this way
interfering with the production of cytokines. The potential risks
of continuing immunosuppression in COVID-19, such as increased
viral replication or prolonged viral shedding, should be balanced
against the benefits of preventing organ transplant rejection.
Willicombe et al. describe the favorable outcomes of 11 SOT
recipients with COVID-19, who all were receiving CNIs at the time
of diagnosis [1]. In the mean time, an increasing number of case
reports and case studies support the hypothesis of these authors,
showing relatively mild COVID-19 in patients with heart-, lung-,
liver- and renal transplantation [2,3]. The majority of these patients
were on CNI therapy and the dosis remained unchanged during
COVID-19, showing favorable outcomes in almost all patients
[2]. A beneficial role of CNI was also supported by another study
in SOT recipients suffering from COVID-19 who where unter CNI
treatment after SOT [4]. These findings suggest that the severity
of COVID-19 is less in SOT recipients, who are on chronic dual or
triple immunosuppression, compared to the general population.
The role of immunosuppression by CNI in patients with COVID-19
is probably beneficial.
In Severe Acute Respiratory Syndrome (SARS), caused by
another coronavirus (SARS-CoV-1), it was shown that cyclosporin
suppresses replication of SARS-CoV-1 [5]. Cyclosporin is a CNI that
inhibits calcineurin by binding to cellular cyclophilins (Cyps). Other
coronaviruses, such as the coronavirus NL63, has been shown to
be inhibited by cyclosporine A-derivatives [6]. A positive role of
cyclosporine as first-line therapy has been proposed by Sanchez-
Pernaute et al [7]. Among the CNIs, also tacrolimus (FK506) is of
special interest [8]. By inhibiting calcineurin, and suppressing
the early phase of T-cell activation and expression of cytokines it
diminishes the cellular immune response, and possibly prevents
the cytokine storm in COVID-19. The studies of tacrolimus in other
severe coronaviral diseases merit further investigation of tacrolimus in COVID-19. In SARS-CoV-1, tacrolimus has shown effectiveness in
animal experiments, and in Middle Eastern Respiratory Syndrome
(MERS) tacrolimus was succesfully used in some case reports.
Based on these results, and the outcomes of COVID-19 in SOT
recipients on tacrolimus [2], we suggest that the answer of the
question if we should leave CNIs out of the cytokine storm, should
be a definite “No”. We even would go a step further, and suggest
tacrolimus as part of a possible treatment strategy in moderate
and severe COVID-19 in the general immunocompetent population.
The results of the Spanish TACROVID trial, investigating the role
of tacrolimus as part of the treatment in COVID-19 in the nontransplant
population may shed some light on this issue [9].
The authors have no conflicts of interest. They equally
contributed to the manuscript.
No fundings.
- Willicombe M, Thomas D, Mc Adoo S (2020) COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm? Journal of the American Society of Nephrology 31(6): 1145-1146.
- Hage R, Steinack C, Benden C, Schuurmans MM (2020) COVID-19 in Patients with Solid Organ Transplantation: A Systematic Review. Transplantology 1(1): 1-15.
- Steinack C, Hage R, Benden C (2020) SARS-CoV-2 and Norovirus Co-Infection after Lung Transplantation. Transplantology 1(1): 16-23.
- Cavagna L, Seminari E, Zanframundo G, Gregorini M, Di Matteo A, et al. (2020) Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms 8(7): E977.
- Tanaka Y, Sato Y, Sasaki T (2013) Suppression of coronavirus replication by cyclophilin inhibitors. Viruses 5(5): 1250-1260.
- Carbajo-Lozoya J, Ma-Lauer Y, Malešević M, Theuerkorn M, Kahlert V, et al. (2014) Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Research 184: 44-53.
- Sanchez-Pernaute O, Romero-Bueno FI, Selva-O’Callaghan A (2020) Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia. Reumatologia Clinica.
- Hage R, Steinack C, Schuurmans MM (2020) Calcineurin inhibitors revisited: A new paradigm for COVID-19? The Brazilian Journal of Infectious Diseases.
- (2020) Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury (TACROVID).